In vitro antimicrobial activities of animal-used quinoxaline 1,4-di-N-oxides against mycobacteria, mycoplasma and fungi by Yan Zhao et al.
RESEARCH ARTICLE Open Access
In vitro antimicrobial activities of animal-
used quinoxaline 1,4-di-N-oxides against
mycobacteria, mycoplasma and fungi
Yan Zhao1†, Guyue Cheng2†, Haihong Hao2, Yuanhu Pan1, Zhenli Liu1,3, Menghong Dai2,3* and Zonghui Yuan1,2,3*
Abstract
Background: The quinoxaline 1,4-di-N-oxides (QdNOs) were known as potent antibacterial agents. For the purpose
of evaluating the bioactivity of existing animal-used QdNOs drugs against representative pathogenic microorganism,
the representative drugs of quinoxalines including cyadox, mequindox, quinocetone and their metabolites were
submitted to the in vitro evaluation for antituberculosis, antimycoplasma, antifungal and antiviral activities.
Results: In antituberculosis assays, the prototype compounds were active (MIC = 4 ~ 8 μg/mL) against Mycobacterium
tuberculosis H37Rv and M. bovis. Combined antimicrobial susceptibility test indicated that cyadox, mequindox and
quinocetone combined with rifampicin had additive effect against M. tuberculosis complex with Fractional Inhibitory
Concentration Index (FIC) of 0.75. Results of antifungal assays showed that quinocetone was active against Microsporum
canis with MIC of 8 μg/mL. Antimycoplasma screening showed a generally good activity of quinocetone against
Mycoplasma gallisepticum and Mycoplasma hyopneumoniae, with MIC between 8 and 16 μg/mL. As shown from
the combined antimicrobial susceptibility test, cyadox, mequindox and quinocetone combined with tetracycline
had additive effect against Mycoplasma gallisepticum with FIC of 0.75. These compounds were also submitted to
antiviral assay against infectious bursal disease virus, porcine reproductive and respiratory syndrome virus, porcine
parvovirus and classical swine fever virus. The results obtained showed that these QdNOs and their metabolites
have no inhibitory activity against these viruses in vitro.
Conclusions: QdNOs exhibit antimicrobial activities against mycobacteria, mycoplasma and fungi. This study gives
new insight in further application of QdNOs and offers a way to promote the healthcare of animal husbandry.
Keywords: Quinoxaline 1,4-di-N-oxides, Antituberculosis, Antimycoplasma, Antifungi, Combined antimicrobial
susceptibility test
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Background
The microorganism infection is one of the most serious
threats to human health and animal production all the
time. With the help of antimicrobial agents, we have a
powerful weapon against pathogens. However, the misuse
of antimicrobials has led to the development of drug-
resistant and multidrug-resistant (MDR) microorganisms
[1]. Resistant bacteria are increasing and the interval be-
tween the appearances of new multi-drug resistant species
is happening in short periods of time [2]. As MDR bac-
teria are increasing worldwide, development of new anti-
microbials with enhanced activity is urgently needed [3].
In addition, it is a cost-effective approach to evaluate the
bioactivity of existing drugs that can reverse the resistance
and over turn the actual bacterial profile.
The quinoxaline 1,4-di-N-oxides (QdNOs) have been
known as potent antibacterial agents since 1940s [4].
Animal-used QdNOs are a class of synthetic antibacterial
agents, and the representative drugs, carbadox, olaquin-
dox, mequindox (MEQ) and quinocetone (QCT) have
been widely used in animal production as antibacterial
growth promoters. Previous studies demonstrated that
these drugs were active to many pathogenic microor-
ganisms, including Escherichia coli, Salmonella spp.,
Staphylococcus aureus, Pasteurella multocida, Brachy-
spira hyodysenteriae, etc. [5].Cyadox (CYA) is a new
member of QdNOs, which may substitute olaquindox
and carbadox because of its low toxicity and broad
antibacterial spectrum [6–9]. Over the last two de-
cades, many papers have been published, in which both
synthesis and biological activity assessment of a large
number of QdNOs derivatives have been described
[10, 11]. Recent studies have demonstrated that QdNOs
are endowed with antituberculosis [12, 13], antiviral
[14], antichagasic [15], anticandida [16] activities and
property of hypoxic selectivity [17], depending on spe-
cific chemical features. The previous encouraging results
prompted us to further analyze the biological activity of
the animal-used QdNOs.
For the purpose of obtaining new and more potent drugs
which can improve the current chemotherapy against rep-
resentative pathogenic microorganism, CYA, QCT, MEQ
and their metabolites were evaluated for in vitro antimicro-
bial activity. The antimicrobial minimum inhibitory con-
centration (MIC) of QdNOs and their metabolites against
fungi, mycoplasma and Mycobacterium tuberculosis com-
plex were examined. Also, the inhibitory activity of QdNOs
against infectious bursal disease virus (IBDV), porcine re-
productive and respiratory syndrome virus (PRRSV) and
porcine parvovirus (PPV) were evaluated by cytopathic
effect (CPE) method and methyl thiazolyl tetrazolium
(MTT) method. Since the replication of classical swine
fever virus (CSFV) does not result in cytopathic effect
in vitro, a SYBR Green I real-time RT-PCR was developed
to determine the copies of the virus suspension. By com-
paring the growth curve, whether these QdNOs have anti-
CSFV activity can be judged. Meanwhile, the combined
antimicrobial susceptibility test were carried out in order
to screen the drug combinations against M. tuberculosis
complex and mycoplasma, providing the scientific basis
for the further application of these drugs.
Methods
Bacteria, viruses and cells
The fungi including Aspergillus fumigatus 3.5301 and
3.5352, Candida albicans 2.4122 and 2.3990 (ATCC7349),
C. tropicalis 2.1975 (ATCC7349) and 2.2735, C. parapsilo-
sis 2.1846 (ATCC22019), Cryptococcus neoformans 2.3201,
Trichophyton rubrum ATCC4438 and CMCC(F)T1I, Epi-
dermophyton floccosum CBS566094 and CMCC(F)E3D
and Microsporum canis CMCC(F)M3D and CBS113480,
and the mycoplasma including Mycoplasma gallisepticum
BG44T (CVCC350) and PG31 (CVCC352) and M. hyop-
neumoniae CVCC354 were mainly obtained from China
Veterinary Culture Collection Center (CVCC). The Myco-
bacterium tuberculosis H37Ra ATCC25177, H37Rv ATCC
27294 and M. bovis ATCC19210 were provided by State
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Key Laboratory of Agricultural Microbiology, Huazhong
Agricultural University (Wuhan, China).
IBDV AV150, PRRSV CAU0680, PPV AV31 and CSFV
AV1412 were obtained from CVCC. The 50 % tissue cul-
ture infective dose (TCID50) for the virus was determined
by the Reed-Muench assay. The IBDV, PRRSV and
PPV were diluted to 1 × 10-6.25 (100 TCID50), 1 × 10
-4.3
(100 TCID50) and 1 × 10
-4.6 (100 TCID50) respectively
with basic medium and stored at −80 °C for future use.
Marc-145 cells, PK-15 cells and DF-1 cells were diluted
to 2 × 105 cells/mL with 10 % Dulbecco’s minimum essen-
tial medium (DMEM), seeded in 96-well plates, and incu-
bated at 37 °C in a 5 % CO2 atmosphere.
Antimicrobials
CYA, bi-deoxy Cyadox (Cy1), N4-deoxy cyadox (Cy2),
N1-deoxy cyadox (Cy10), QCT, carbonyl reduction bi-
deoxy quinocetone (Q2), MEQ, bi-deoxy Mequindox (M1),
carbonyl reduction N1-deoxy mequindox (M4), carbonyl
reduction bi-deoxy mequindox (M5) and carbonyl re-
duction mequindox (M6) (Table 1) were provided by
the National Reference Laboratory of Veterinary Drug
Residues, Huazhong Agricultural University (Wuhan,
Hubei, China). Amphotericin B, tetracycline, doxycycline,
ketoconazole, enrofloxacin, danofloxacin, rifampicin, til-
micosin and kitasamycin were purchased from Dr. Ehren-
storfer (Augsburg, Germany). Kanamycin, pyrazinamide,
lincomycin, ethambutol, ribavirin and isoniazid were pur-
chased from TRC (Toront, Canada). Amikacin, clindamy-
cin, and tylosin were purchased from Sigma (St Louis,
MO, USA). Stock solutions of the above compounds were
prepared at a final concentration of 1280 μg/mL.
Reagents
Porcine mycoplasmas medium, Middlebrook 7H9 broth
base medium, Mycoplasma gallisepticum medium and
Yeast Peptone Dextrose (YPD) medium were purchased
from Qingdao Hope Bio-Technology Co., Ltd (Qingdao,
Shandong, China). 1640 medium and horse serum were
bought from Gibco (GrandIsland, NY, USA).
DMEM (Hyclone, Beijing, China) supplemented with
10 % or 2 % heat-inactivated fetal calf serum (FCS;
Hyclone, USA), 100 IU/ml penicillin G and 100 μg/mL
streptomycin was used for cell growth or maintenance
medium. A 0.25 % trypsin (Hyclone, Beijing, China) was
prepared in pH 7.2 phosphate buffer saline (PBS). A
0.5 % 3-(4,5-dimethyithiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (Biosharp, Hefei, Anhui, China) was pre-
pared in PBS. These solutions were sterilized through a
0.22 μm Millipore membrane filter. Dimethyl sulfoxide
(DMSO) was purchased from Sigma (St Louis, MO, USA).
pMD18-T vector, M-MLV Rtase, Rnasin, Trans1-T1 com-
petent cell, SYBR Premix Ex TaqTM II (Tli RNaseH Plus)
were purchased from TaKaRa (Dalian, Liaoning, China).
Plasmid Minipreparation Kit and Axyprep DNA Gel
Extraction Kit were the products of TIANGEN biotech
Co., Ltd (Beijing, China). Trizol Regent was purchased
from Ambion (Shanghai, China). All other chemicals
and reagents commercially available were of the highest
analytical grade.
Microdilution alamar blue assay (MABA) against
M. tuberculosis complex
The activities of QdNOs and their metabolites as well as
the positive control drugs isoniazide and rifampicin against
M. tuberculosis complex strains were tested using MABA
[18]. Briefly, each of the above Mycobacterium strains was
cultured at 37 °C in Middlebrook 7H9 broth supplemented
with 0.2 % glycerol and 10 % Oleic Acid-Albumin-
Dextrose-Catalase (Sigma, St Louis, MO, USA) until
logarithmic growth was reached. About 6 × 106 CFU/mL
inoculum of Mycobacterium strain was then added to the
two fold serially diluted drug samples. The final concentra-
tion of DMSO in all assays was 2.5 % or less and this dilu-
tion also served as solvent control. The samples were
assayed in triplicate. All tests were carried out in sterile flat
bottom 96-well microplates. Each microplate was incu-
bated for 5 days at 37 °C in a sealed plastic CO2-permeable
bag. After 7 days of incubation, 32 μL of a mixture of
freshly prepared Alamar Blue solution and 20 % sterile
Tween-80 at 1:1 (v/v) were added to the growth-control
well. The microplates were incubated at 37 °C for 24 h. If a
color shift from blue to pink was observed in the growth-
control sample, 32 μL of Alamar Blue solution was added
to each of the remaining wells, and the microplate was fur-
ther incubated for 24 h. A well-defined pink color was
interpreted as positive bacterial growth, whereas a blue
color indicated an absence of growth. The MIC corres-
ponded to the concentration of the greatest dilution of
drug sample in which the color shift from blue to pink was
not observed.
Antifungal assay
The antifungal activity of the QdNOs and their metabo-
lites as well as the positive control drugs amphotericin
B and ketoconazole were determined according to
Rodriguez-Tudela et al. [19]. Briefly, the compounds
were tested by macrobroth 2-fold serial dilution tech-
nique. Aspergillus fumigatus, Candida albicans, Cryptococ-
cus neoformans, Candida tropicalis, Candida parapsilosis,
Trichophyton rubrum, Epidermophyton floccosum and
Microsporum canis seeded broth (105 CFU/mL) were pre-
pared in RPMI 1640 medium, and added into the serially
diluted drug solution. The tubes were incubated at
28 °C and the MIC (μg/mL) was recorded after 72 ~
96 h (mycelial fungi) post-incubation. Broth control
(without fungi), growth controls (with fungi and with-
out drug), solvent (DMSO) control and drug control
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Table 1 Chemical information of QdNOs and their metabolites
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of both test drugs and standard drugs were set under
identical conditions. The minimum drug concentra-
tion in the tubes in which no apparent growth of the
organism was observed represented the MIC of the
compound.
Antimycoplasma assay
The MIC determination of QdNOs and their metabolites
and the positive control drugs, tylosin and enrofloxacin,
against mycoplasma was performed according to Hannan
[20]. Briefly, 96-well microtiter Sensititre plates containing
stabilized and freeze-dried antimicrobials were used.
Three wells on each plate were set as antimicrobial free
growth control. Freshly thawed mycoplasma isolates
with known titers were diluted in liquid medium until
the number of organisms reached 104 color changing
units/mL. 50 μL of the diluted culture was transferred
into each well of the Sensititre plates. The M. gallisepticum
PG31 was used as the control strain and tested three times
in order to estimate the reproducibility of the procedure.
The plates were sealed using an adhesive foil and incubated
at 36 °C for 14 days. The growth of M. hyopneumoniae
was observed daily when the color of the medium changed
from red to yellow (phenol red indicator), and the initial
and final MICs were recorded. The initial MIC was defined
as the lowest drug concentration at which no change in
color when the growth control turned yellow, and the final
MIC was defined as the lowest drug concentration to show
no color change at 14 days after inoculation.
Combination susceptibility assay
The fractional inhibitory concentration (FIC) index is
most frequently used to describe drug interactions. The
combined effects of CYA, MEQ and QCT with antimy-
coplasma drugs (tetracycline, doxycycline, lincomycin,
clindamycin, danofloxacin, enrofloxacin, tylosin and kita-
samycin) against M. gallisepticum were studied using the
checkerboard method [21]. Meanwhile, the combined
effects of CYA, MEQ and QCT with antituberculosis drugs
(rifampicin, isoniazid, streptomycin, kanamycin, etham-
butol, and amikacin) against M. tuberculosis H37Rv and
M. bovis were studied in the same way. FICs were calcu-
lated according to the equation: FIC = FICA+ FICB = A/
MICA+ B/MICB, where A and B are the MICs of drug A
and drug B in the combination, MICA and MICB are the
MICs of drug A and drug B alone. Experiments were
performed in duplicate. The FIC indices were inter-
preted as follows: ≤0.5, synergy; 0.5 to 1, additive; 1 to 2,
indifferent; >2, antagonism [22].
Cytotoxicity assay
The cytotoxicity of the QdNO compounds and their me-
tabolites was measured by MTT assay [23]. Each com-
pound or the control drug ribavirin was 2-fold serially
diluted with DMEM containing 2 % FCS, respectively.
Marc-145 cells, DF-1 cells, and PK-15 cells were seeded
into 96-well plates at a density of 2 × 104 cells/well, and
incubated for 24 ~ 36 h. When the cells were at least
90 % confluent, the medium was removed and the di-
luted compounds or ribavirin were added to the wells
and incubated for 72 h. Then, the medium was dis-
carded and 20 μL of MTT solution was added to each
well. The plates were then further incubated at 37 °C for
4 h. Subsequently, the supernatant was removed and
150 μL of DMSO was added to each well in order to dis-
solve the formazan crystals. After gently shaking the
plates for 10 min, the absorbance was read on an ELISA
microplate reader with a 490 nm wavelength and a
630 nm reference wavelength.
For each compound, the percentage of cell viability
was calculated as [(A-B)/A × 100], where A and B cor-
respond to the absorbance of control and treated cells,
respectively. The 50 % cytotoxic concentration (CC50)
value was defined as the concentration of each com-
pound that reduced the absorbance of treated cells by
50 % when compared with the non-treated cell control.
The maximum non-cytotoxic concentration (MNTC)
was calculated as the maximum drug concentration to
retain 90 % cell viability [24].
Antiviral assay
The anti-PRRSV, anti-PPV and anti-IBDV activities of
the QdNO compounds and their metabolites were evalu-
ated as previously described by Li et al. [25] with minor
modifications. Briefly, a confluent monolayer of cells was
prepared as described above. After removal of the cul-
ture medium, the MNTC of each compound and a con-
stant amount of 100 TCID50 viruses were added. Cell
control, virus negative control, and ribavirin positive
control were set up simultaneously. The plates were then
incubated at 37 °C. When CPE in the virus negative control
reached 80 %~ 90 % compared with cell control, the cell
viability was determined by the MTT method. The inhibi-
tion ratio was calculated based on the formula [26]: Inhibi-
tion ratio = [(ODT)virus-(ODC)virus]/[(ODC)mock-(ODC)virus],
where (ODT) virus represents the optical density (OD) of
cells infected with virus and treated with the compounds,
(ODC)virus corresponds to the OD of the untreated virus-
infected cells, and (ODC)mock is the OD of untreated mock-
infected cells. The compounds with the inhibition ratio ex-
ceeding 50 % were selected and made by a 2-fold serial di-
lution with MM, and the procedures were repeated as
described above. The 50 % effective concentration (EC50) of
the compound was defined as 50 % cytoprotection against
virus infection. The selectivity index (SI) was calculated as
the ratio of CC50 to EC50. When EC50 could not be calcu-
lated owing to low inhibition ratio of CPE, the results were
counted as the maximum inhibition ratio.
Zhao et al. BMC Veterinary Research  (2016) 12:186 Page 5 of 13
For the virucidal assay [27], each compound with the
MNTC and 100 TCID50 viruses were mixed and inter-
acted at 37 °C for 2 h. 100 μL of virus/compound sus-
pension was then added to a cell plate and incubated at
37 °C in a 5 % CO2 humidified atmosphere. The plate
was observed under a microscope daily until the CPE of
the virus negative control reached 80 % ~ 90 % com-
pared with cell control, and the MTT test was per-
formed as described above.
The infection inhibition assay was done dynamically
according to previous methods [28] with some modifica-
tions. The cells in 96-well plates were pre-incubated
with 100 TCID50 viruses for 2 h. Subsequently, the
medium was removed and the cells were washed twice
with PBS, and then fresh medium containing MNTC of
each compound was added. The plates were further in-
cubated at 37 °C in 5 % CO2 atmosphere. The CPE was
recorded at a time interval of 12 h under the micro-
scope. When the CPE of the virus negative control
reached 80 % ~ 90 % compared with cells control, the
anti-virus activity of all phases was assessed by MTT test
and the viral inhibition ratio was calculated.
The adsorption inhibition assay was done as followings
[29]. The confluent monolayers of cells grown in 96-well
plates were incubated with the compounds at 37 °C in a
5 % CO2 atmosphere for 4 h. Subsequently, the medium
was removed and 100 TCID50 viruses were added to
each well and incubated for 1 h. The cell monolayer was
gently washed with PBS and then fresh medium was
added to the plates. The plates were incubated at 37 °C
in a humidified atmosphere of 5 % CO2 until 80 ~ 90 %
CPE was observed in virus negative control compared
with cells control. The MTT test and viral inhibition
ratio were then determined as above.
Anti-CSFV assay
CSFV replication is restricted to the cell cytoplasm and
does not result in cytopathic effect [30], therefore it was
not possible to observe directly the foci of viral growth.
Due to this fact, a real-time quantitative PCR (RT-qPCR)
using SYBR Green I was developed to determine the
copies of virus suspension.
The RNA was extracted from cell culture superna-
tants of CSFV-infected PK-15 cells using the Trizol
method according to the manufacturer’s instructions
(Ambion Shanghai, China). The synthesis of cDNA was
performed by random priming and using M-MLV re-
verse transcriptase, as described previously by De Arce
et al. [31]. PCR primers (HCLV-FP: 5′-GCAGAAGCCC
ACCTCGAGAT-3′; HCLV-RP: 5′-TACACCGGTTCCTC
CACTCC-3′) synthesized by TIANYI HUIYUAN (Wuhan,
Hubei, China) were used to amplify a 244-bp frag-
ment of the conserved 5′-UTR of the genome of hog
cholera virus strain HCLV (sequence is available in
GenBank no. AF09150). The 50 μL reaction mixture
contained 31.0 μL sterilized water, 5.0 μL of 10× buffer,
5.0 μL of dNTP Mixture, 3 μL of MgCl2 (25 mmol/L),
1 μL of each primer (HCLV-FP and HCLV-RP), 1 μL of re-
verse transcription product, and 3 μL of Ex Taq™ DNA
Polymerase (Ex taq). The thermal conditions were set as
follows: one cycle at 94 °C for 3 min; followed by 35 cycles
at 94 °C for 30 s, 59 °C for 30 s, and 72 °C for 30 s; with a
final extension at 72 °C for 7 min.
The PCR product was inserted into the vector
pMD18-T to construct the recombinant plasmid p-18 T-
HCLV which was transformed into in E. coli DH5α host
bacteria. After increased in the host bacteria, the re-
combinant plasmid was purified using Plasmid Mini-
preparation Kit (TIANGEN), and kept at −20 °C for
later use.
The real-time PCR amplifications of the target gene
fragments used 25 μL reaction mixtures containing
12.5 μL of SYBR premix, 1 μL of cDNA, 0.5 μL of each
primer, and 10.5 μL sterile water. The reactions were
carried out in BIO-RAD iQ5 Real Time PCR (Hercules,
CA, USA). The conditions were as follows: one cycle at
94 °C for 3 min followed by 40 cycles at 94 °C for 30 s,
59 °C for 30 s, and 72 °C for 30 s. Analytical sensitivity
was evaluated by testing standard plasmid p-18T-HCLV
from sequential ten fold dilutions in DEPC treated water
(3.74 ~ 3.74 × 108 copies/μL).
To determine the reproducibility of the real-time
PCR, the standard plasmid was diluted to 3.74 × 104,
3.74 × 105 and 3.74 × 106 copies/μL respectively in
DEPC treated water. To evaluate intra-assay variability,
each dilution was analyzed in triplicate. To measure
inter-assay variability, each dilution was analyzed in
three different runs performed by two different opera-
tors on different days. Coefficients of variation for cycle
threshold (Ct) values within each block and among
blocks (using the mean values from each block) were
determined.
The anti-CSFV assay was done dynamically following
previous methods. The MNTC of each compound and
CSFV AV1412 were used in the assay. The PK-15 cells
in 96-well plates were pre-incubated with CSFV for 2 h.
Subsequently, the medium was removed and the cells
were washed twice with PBS, and then fresh medium
containing the compounds was added. The plates were
further incubated at 37 °C in 5 % CO2 atmosphere. The
cell culture supernatants and CSFV-infected PK-15 cells
were collected at 12 h, 24 h, 36 h, 48 h, 72 h, 84 h, 96 h
and 108 h respectively. Cells control and virus negative
control were set up simultaneously. After RNA isolation
and cDNA synthesis, the samples were subjected to the
RT-qPCR to detect the copy number. By comparing the
growth curve, whether QdNOs have anti-CSFV activity
could be judged.
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Statistical analysis
The statistical analysis was performed using the SPSS
19.0 software. Each experiment was repeated three or
more times. Data were represented as the means for repli-
cate samples of independent experiments and expressed
as the mean ± SD. A student’s t-test and one-way ANOVA




The results of the in vitro evaluation of antifungal activity
of QdNOs are shown in Table 2. The MICs of the quality
control drug, amphotericin B and ketoconazole, against
the C. parapsilosis and C. albicans all fell within the same
range compared with the results of the previous study
[19]. The MIC of CYA against Cryptococcus neoformans
was determined to be 16 μg/mL and QCT was the
most active against Microsporum canis with the MIC
of 8 μg/mL. The results suggested that QCT could
inhibit the growth of superficial fungi and CYA had in-
hibitory activity against both superficial fungi and deep
fungi. The deoxidized metabolites of QdNOs (Table 1)
were ineffective against fungi, indicating that the presence
of the two N-oxide groups in the quinoxaline ring is
necessary to the antifungal activity.
Atimycoplasma activity
The antimycoplasma susceptibility test results of 3
QdNOs and 8 antimycoplasma drugs are shown in Table 3.
The MICs of the control drugs, tylosin and enrofloxacin,
against M. gallisepticum and M. hyopneumoniae were the
same or within 2-fold difference as those in the previous
findings [20]. The date obtained indicated the effectiveness
of the three QdNO drugs against mycoplasma with MICs
between 8 to 32 μg/mL. The MIC of QCT against M.
gallisepticum was determined to be 8 μg/mL. The metabo-
lites of QdNOs were ineffective against mycoplasma, indi-
cating that the presence of the two N-oxide groups ring is
necessary to the antimycoplasma activity.
The MICs of other 8 antimycoplasma drugs showed a
good activity against M. gallisepticum (Table 3). As shown
in Table 4, CYA, MEQ and QCT combined with tetracy-
clines (tetracycline and doxycycline) had additive effect
against M. gallisepticum.
Antituberculosis activity
The results of antituberculosis activity of QdNOs are
shown in Table 5. The MICs of of the quality control
drugs (rifampicin and isoniazid) against M. tuberculosis
H37Rv ATCC27294 were within 2-fold difference range
as those in the previous studies [32, 33]. The three
QdNO drugs showed good effectiveness against M. bovis
and M. tuberculosis H37Rv with the MICs between 4 to
8 μg/mL. The QdNO metabolites were ineffective against
M. tuberculosis complex, confirming the findings of the
report that the presence of the two N-oxide groups in
the quinoxaline ring is necessary to the antitubercular
activity [34].
The results of the MICs of other seven antituberculosis
drugs showed a good activity against M. tuberculosis com-
plex (Table 5). As can be seen from Table 6, CYA, MEQ
Table 2 MICs of QdNOs against fungi
(Unit: μg/mL)
Fungi CYA QCT MEQ AMB KCZ
Superficial fungi M. canis CBS113480 16 8 >64 0.5 0.25
M. canis CMCC(F)M3D 32 16 >64 1 0.5
T. rubrum ATCC4438 32 32 >64 1 0.5
T. rubrum CMCC(F)T1I 32 32 >64 1 0.5
E. floccosum CBS566094 32 32 64 0.5 0.25
E. floccosum CMCC(F)E3D 32 32 >64 0.5 0.25
Deep fungi C. albicans 90028 64 >64 64 1 0.25
C. albicans 2.4122 32 >64 32 2 0.5
C. tropicalis 7349 32 >64 >64 2 0.5
C. tropicalis 2.2735 32 >64 64 2 0.5
C. parapsilosis 22019 32 64 64 1 0.125
C. neoformans 2.3201 16 64 32 0.5 0.25
A. fumigatus 3.5352 32 64 >64 0.5 0.5
A. fumigatus 3.5301 64 64 >64 0.5 0.25
AMB amphotericin B, KCZ ketoconazole
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and QCT combined with rifampicin had additive effect
against M. tuberculosis complex with FIC of 0.75.
Antiviral activity
Cytotoxicity assays are essential for the initial phases of
antiviral drug development. The MNTC and CC50 values
for each tested compound are listed in Table 7. It was
observed that CYA, MEQ and QCT exhibited more
cytotoxicity than their metabolites to Marc-145 cells, PK-
15 cells and DF-1 cells except Q2. The test compounds
showed CC50 values ranging from 0.81 to 128.62 μg/mL,
and the MNTC ranged from 0.06 to 4.0 μg/mL.
The results obtained from the anti-PRRSV, anti-PPV
and anti-IBDV assay demonstrated that QdNOs and
their metabolites showed no effectiveness against these
viruses in vitro (Additional files 1, 2 and 3). The control
drug ribavirin possessed good inhibitory activity in infec-
tion inhibition assay, virucidal assay and adsorption in-
hibition assay.
In the Anti-CSFV assay, the plasmid p-18T-HCLV
containing a 244 bp gene fragment of HCLV was used as
Table 3 MICs of QdNOs and other antibacterials against
mycoplasma
(Unit: μg/mL)









CYA 32 16 16 16
QCT 8 16 16 16
MEQ 16 16 32 32
Tylosin 0.05 0.025 0.025 0.05







Table 4 In vitro activity of QdNOs in combination with various antibacterials against Mycoplasma gallisepticum
Drug combination M. gallisepticum PG31 M. gallisepticum BG44T
FICA + FICB FIC Combined effect FICA + FICB FIC Combined effect
CYA + Tetracycline 0.25 + 0.5 0.75 additive 0.25 + 0.5 0.75 additive
CYA + Doxycycline 0.5 + 0.5 1 additive 0.5 + 0.5 1 additive
CYA + Lincomycin 0.5 + 0.25 0.75 additive 0.25 + 1 1.25 indifferent
CYA + Clindamycin 0.5 + 0.5 1 additive 0.25 + 1 1.25 indifferent
CYA + Danofloxacin 0.5 + 1 1.5 indifferent 0.25 + 1 1.25 indifferent
CYA + Enrofloxacin 0.25 + 1 1.25 indifferent 0.25 + 1 1.25 indifferent
CYA + Tylosin 0.5 + 0.5 1 additive 1 + 0.5 1.5 indifferent
CYA + Kitasamycin 0.25 + 1 1.25 indifferent 0.5 + 0.5 1 additive
QCT + Tetracycline 0.25 + 0.5 0.75 additive 0.25 + 0.5 0.75 additive
QCT + Doxycycline 0.5 + 0.5 1 additive 0.5 + 0.5 1 additive
QCT + Lincomycin 0.5 + 0.5 1 additive 0.25 + 1 1.25 indifferent
QCT + Clindamycin 0.25 + 1 1.25 indifferent 0.25 + 1 1.25 indifferent
QCT + Danofloxacin 0.25 + 1 1.25 indifferent 0.5 + 0.5 1 additive
QCT + Enrofloxacin 0.25 + 1 1.25 indifferent 0.25 + 1 1.25 indifferent
QCT + Tylosin 0.5 + 0.5 1 additive 0.25 + 1 1.25 indifferent
QCT + Kitasamycin 0.25 + 1 1.25 indifferent 0.25 + 1 1.25 indifferent
MEQ + Tetracycline 0.5 + 0.5 1 additive 0.25 + 0.5 0.75 additive
MEQ + Doxycycline 0.5 + 0.5 1 additive 0.5 + 0.5 1 additive
MEQ + Lincomycin 0.25 + 1 1.25 indifferent 0.25 + 1 1.25 indifferent
MEQ + Clindamycin 0.5 + 0.5 1 additive 0.25 + 1 1.25 indifferent
MEQ + Danofloxacin 0.5 + 1 1.5 indifferent 0.25 + 1 1.25 indifferent
MEQ + Enrofloxacin 0.25 + 1 1.25 indifferent 0.25 + 1 1.25 indifferent
MEQ + Tylosin 0.5 + 0.5 1 additive 0.25 + 1 1.25 indifferent
MEQ + Kitasamycin 0.25 + 1 1.25 indifferent 0.5 + 0.5 1 additive
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standard (Fig. 1). The concentration of the plasmid p-
18T-HCLV was 1.22 μg/μL before dilution, equivalent to
3.74 × 109 copies/μL. Standard curve were plotted by
copy numbers of p-18T-HCLV as the horizontal coordin-
ate and the Ct values as the vertical coordinate based on
results of RT-qPCR. The standard curve was linear in the
range from 109 to 102 copies/μL, with R2 of 0.995 and a
reaction efficiency of 99.23 % (Fig. 2). The limit of
detection of the RT-qPCR method was 3.74 × 101 cop-
ies/μL and the linear range spanned from 3.74 × 108 to
3.74 × 101 copies/μL (Additional file 4). The dissoci-
ation curve analysis performed after the completed
PCR confirmed only Tm of 86.6 °C for the amplified
template (Additional file 5). The amplification plot as
well as the melting curve showed nonspecific amplifica-
tion and non-specific primer dimerization. The amplifi-
cations were highly reproducible with coefficients of
variation within runs (intra-assay variability) ranging
from 0.13 % to 0.80 %, and inter-assay variability ran-
ging from 0.29 % to 0.43 %. By comparing the growth
curves we can observe that there are no significant
changes of the copies of CSFV between the blank con-
trol and the drug-treated group (Fig. 3), indicating that
QdNOs have no inhibitory activity against CSFV.
Discussion
Antonio and coworkers [10] first reported the synthesis
and anticandida activities of 36 6(7)substituted-3-methyl-
or3-halogenomethyl-2-phenylthio-phenylsulphonyl-chloro-
QdNOs. It was shown that the QdNO derivaties without
6(7)-substituted had MIC50 of 31.25 μg/mL against 24
clinical-isolated C. albicans, consistent with our results
(Table 2). Based on the reports and our results, the
QdNOs have a general good antifungal activity.






H37Rv ATCC 27294 H37Ra ATCC 25177
CYA 8 4 64
QCT 4 4 64
MEQ 8 4 32
Rifampicin 0.025 0.05 1.6






Table 6 In vitro activity of cyadox, quinocetone and mequindox in combination with various antibacterials against Mycobacterium
tuberculosis complex
Drug combination M. bovis ATCC 19210 M. tb H37Rv ATCC 27294
FICA + FICB FIC Combined effect FICA + FICB FIC Combined effect
CYA + Rifampicin 0.5 + 0.25 0.75 additive 0.5 + 0.25 0.75 additive
CYA + Isoniazide 1 + 0.5 1.5 indifferent 1 + 0.25 1.25 indifferent
CYA + Streptomycin 0.5 + 0.25 0.75 additive 0.5 + 0.5 1 additive
CYA + Kanamycin 1 + 0.5 1.25 indifferent 1 + 0.5 1.5 indifferent
CYA + Ethambutol 1 + 0.5 1.5 indifferent 1 + 0.25 1.25 indifferent
CYA + Amikacin 1 + 0.5 1.5 indifferent 1 + 0.25 1.25 indifferent
QCT + Rifampicin 0.5 + 0.5 1 additive 0.5 + 0.25 0.75 additive
QCT + Isoniazide 1 + 0.5 1.5 indifferent 1 + 0.25 1.25 indifferent
QCT + Streptomycin 0.5 + 0.5 1 additive 1 + 0.25 1.25 indifferent
QCT + Kanamycin 1 + 0.5 1.25 indifferent 1 + 0.5 1.5 additive
QCT + Ethambutol 1 + 0.5 1.5 indifferent 1 + 0.25 1.25 indifferent
QCT + Amikacin 0.5 + 0.5 1 additive 1 + 0.5 1.5 indifferent
MEQ + Rifampicin 0.5 + 0.5 1 additive 0.5 + 0.25 0.75 additive
MEQ + Isoniazide 1 + 0.5 1.5 indifferent 1 + 0.25 1.25 indifferent
MEQ + Streptomycin 1 + 0.5 1.55 additive 1 + 0.5 1.5 additive
MEQ + Kanamycin 1 + 0.5 1.5 indifferent 0.5 + 0.5 1 additive
MEQ + Ethambutol 1 + 0.5 1.5 indifferent 1 + 0.5 1.5 indifferent
MEQ + Amikacin 1 + 0.5 1.55 indifferent 1 + 0.5 1.5 indifferent
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There were few reports on QdNOs against myco-
plasma. 23 QdNO derivaties were synthesized and sub-
mitted to antimycoplasma assay against Mycoplasma
hominis, and the results showed several compounds
inhibited the growth of the mycoplasma at the concen-
tration of 0.1 mg/mL [16]. Based on our results, the
QdNOs may have a better antimycoplasma activity against
M. gallisepticum and M. hyopneumoniae (Table 3).
The report about the antiviral activity of quinoxalines
focused on derivatives of indoloquinoxaline. The anti-
viral effect of indoloquinoxaline depends on its intercal-
ating into the DNA helix and then disturbing steps that
are vital for viral uncoating [14]. The QdNOs were
redox-activated, hypoxia-selective DNA cleaving com-
pouds [35]. In our study, neither QdNOs nor their me-
tabolites showed antiviral activity, probably due to the
differences in chemical structures of the tested QdNOs
and indoloquinoxaline in which the indole groups might
be more important for antiviral activity.
Over the past few years, QdNO derivatives have grad-
ually become a research hotspot because they are found
to possess good activity against M. tuberculosis. What is
more, one of the five lead compound series which are
currently pursued under the Tuberculosis Antimicrobial
Acquisition and Coordinating Facility (TAACF) program
is the series of QdNOs derivatives [12]. Over 500 qui-
noxaline derivatives were tested by the TAACF program,
many of these compounds possess good antitubercular ac-
tivity, and some analogs were even found active against
single-drug-resistant strains and non-replicating bacteria
[36]. In our study, MEQ showed antitubercular activity
Table 7 Cytotoxic features of QdNOs and their main metabolites in PK-15, Marc-145 and DF-1 cells
(Unit: μg/mL, mean ± SD, n = 4)
Drugs PK-15 Marc-145 DF-1
TC50 MNTC TC50 MNTC TC50 MNTC
CYA 15.31 ± 1.23 1.2 16.92 ± 1.28 1.56 17.26 ± 1.27 1.0
Cy1 23.40 ± 2.14 2.0 37.83 ± 1.67 3.9 32.97 ± 2.35 2.0
Cy2 51.73 ± 2.96 2.0 96.55 ± 3.12 2.0 35.48 ± 2.87 1.0
Cy10 25.27 ± 1.55 2.0 33.62 ± 1.85 2.0 49.2 ± 1.93 2.0
QCT 2.38 ± 0.27 0.2 8.90 ± 1.05 0.39 9.89 ± 1.08 0.25
Q2 0.81 ± 0.12 0.1 3.76 ± 0.59 0.2 1.86 ± 0.24 0.06
MEQ 17.86 ± 1.28 0.5 41.28 ± 1.28 1.0 40.01 ± 1.27 2.0
M1 72.90 ± 2.66 2.0 70.77 ± 1.57 1.0 54.8 ± 1.93 1.0
M4 40.81 ± 1.27 3.9 128.62 ± 2.67 3.9 37.75 ± 2.68 1.0
M5 40.41 ± 3.21 2.0 89.66 ± 2.14 2.0 38.2 ± 2.09 2.0
M6 78.82 ± 3.57 2.0 89.82 ± 1.57 2.0 41.26 ± 1.27 2.0
Ribavirin 44.80 ± 1.58 2.0 75.49 ± 2.54 8.6 67.42 ± 2.58 4.0
Fig. 1 The PCR amplification result of recombinant plasmid p-18T-HCLV.
Lane M, DL2000DNA Marker; lane 1 to 4, target fragment; lane 5,
blank control
Fig. 2 The standard curve for FQ-PCR of standard plasmid. The
LogConcentration in the X-axis indicates the denary logarithm of
the copy number of standard plasmid per microliter
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against M. tuberculosis H37Rv with MIC of 4 μg/mL, in
consistence with the previous report (3.13 μg/mL) [11].
The available information so far and our results support
the interest devoted to QdNOs as a novel class of antitu-
berculosis agents.
It has been shown that the potency of the quinoxalines
make them valid leads for synthesizing new compounds
that possess better activity, especially the activity against
M. tuberculosis. The application of the quantitative
structure-activity relationship (QSAR) serves as a ra-
tional guide for the design of QdNO derivatives [37].
With the help of the resourceful tool, we can not only
synthesize more novel antitubercular candidates, but
also modify the old existing quinoxaline drugs.
Synergistic and additive combinations of two or more
agents can overcome toxicity and other side effects asso-
ciated with high doses of single drugs by countering bio-
logical compensation, allowing reduced dosage of each
compound or accessing context-specific multitarget mech-
anisms [38, 39]. Combinations of CYA, MEQ and QCT
with other antibacterials showed only additive and indif-
ferent interaction with FIC index of 0.75 ~ 1.5. Neither
antagonism nor synergism in the QdNO-antibacterial
combinations against M. gallisepticum and M. tubercu-
losis complex were observed. The results of this in vitro
trial provide evidence that CYA, MEQ and QCT, when
combined with other antibacterials, could produce a
clinically relevant additive effect against these pathogens,
without any antagonistic interaction. Therefore, QdNOs
may serve as promising compounds for future treatment
and prevention of mycoplasmal and tuberculosis
infections.
Conclusion
This study confirmed for the first time that QdNOs have
good inhibitory activity against Mycobacterium tubercu-
losis complex and Mycoplasma, and they may reduce the
threat of drug resistance emerging from those two import-
ant pathogens by effective drug combinations. Moreover,
this study developed a method for evaluating drugs against
CSFV in vitro, providing a new alternative to screen the
anti-CSFV drugs. This study gives new insight in further
application of QdNOs and offers a way to promote the de-
velopment of animal husbandry.
Additional files
Additional file 1: The result of antiviral activity of QdNOs and their
metabolites against PRRSV. (DOCX 18 kb)
Additional file 2: The result of antiviral activity of QdNOs and their
metabolites against PPV. (DOCX 18 kb)
Additional file 3: The result of antiviral activity of QdNOs and their
metabolites against IBDV. (DOCX 18 kb)
Fig. 3 The curve of virus replication after culture with QdNOs and its main metabolites (mean ± SD, n = 4). PK-15 cells were incubated with CSFV
for 2 h, and then fresh medium containing the compounds (A: CYA, QCT, and MEQ; B: Cy1, Cy2, and Cy 10; C: Q2; D: M1, M4, M5, and M6)
was added. The cell culture supernatants and CSFV-infected PK-15 cells were collected at 12 h intervals. After RNA isolation and cDNA
synthesis, the samples were subjected to the real-time PCR to detect the copy number. The LogConcentration in the Y-axis indicates the
denary logarithm of the copy number of CSFV per microliter. BK, blank control
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Additional file 4: The amplification dynamic curve of RT-qPCR of standard
plasmid. (DOCX 342 kb)
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